IQVIA Holdings Inc. Q2 2026 Earnings Recap

The stock surged 16.1% post-earnings, driven by clear beats across revenue, adjusted EBITDA, and EPS, with organic and segment-level growth outpacing prior expectations and margins expanding earlier than anticipated.

Key Takeaways

• Reported revenue grew 8.7% year-over-year, exceeding the high-end of guidance despite lower-than-expected FX tailwinds; organic growth accelerated to 6%.
• Adjusted EBITDA rose 9.2% year-over-year, surpassing the top end of guidance, supported by better-than-expected operational performance and margin improvements.
• Adjusted diluted EPS increased 12.1% to $3.15, also above guidance, reflecting strong underlying profitability.
• Clinical R&D bookings hit $3.15 billion, up 19% year-over-year and 27% sequentially, with a book-to-bill ratio of 1.22, signaling sustained demand momentum.
• Commercial segment organic growth accelerated to 5%, with analytics and consulting posting high-single-digit growth, driven by new drug launches and increased AI adoption.